Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic AntibodiesAnnalise Petriello 1, Jacob A. Becerra 2, Jason Lay 1, Reem Husaini 2, Sarah L. Windler 1, Omar Duramad 1, Scot D. Liu 1
1Department of Research and Development, iQ Biosciences, 2Department of Cellular Products, iQ Biosciences
A protocol for studying FcγRIIIa-driven events by therapeutic antibodies in human natural killer cells is described here. This artificial stimulation platform permits the interrogation of downstream effector functions such as degranulation, chemokine/cytokine production, and signaling pathways mediated by the FcγRIIIa and Fc portions of antibodies involved in binding.
